FOLD:NSD-Amicus Therapeutics Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 7.59

Change

-0.35 (-4.41)%

Market Cap

USD 2.17B

Volume

2.02M

Avg Analyst Target

USD 15.00 (+97.63%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


Amicus Therapeutics Inc (FOLD) Stock Analysis:
Based on the Amicus Therapeutics Inc stock forecasts from 3 analysts, the average analyst target price for Amicus Therapeutics Inc is USD 15.00 over the next 12 months. Amicus Therapeutics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Amicus Therapeutics Inc is Slightly Bearish, which is based on 3 positive signals and 5 negative signals. At the last closing, Amicus Therapeutics Inc’s stock price was USD 7.59. Amicus Therapeutics Inc’s stock price has changed by -1.94% over the past week, -3.07% over the past month and -15.48% over the last year.

About

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-05-24 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
GILD Gilead Sciences Inc

+0.69 (+1.08%)

USD80.08B 17.83 11.21
REGN Regeneron Pharmaceuticals Inc

+4.11 (+0.60%)

USD72.62B 9.40 7.18
VRTX Vertex Pharmaceuticals Incorpo..

+0.13 (+0.05%)

USD66.14B 27.29 19.22
MRNA Moderna Inc

-5.56 (-4.04%)

USD54.19B 4.01 2.75
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BNTX BioNTech SE

-8.72 (-5.34%)

USD39.61B 3.12 1.86
RPRX Royalty Pharma plc

-0.31 (-0.77%)

USD26.64B 28.87 15.23
SGEN Seagen Inc

-5.87 (-4.21%)

USD25.70B 55.02 44.86
GMAB Genmab A/S

-0.30 (-0.97%)

USD20.43B 60.76 5.35
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing FOLD

Symbol Name Weight Mer Price(Change) Market Cap
GHII Invesco S&P High Income I.. 5.50 % 0.45 %

N/A

USD0.06B
GRBIC Gabelli RBI NextShares 3.35 % 0.95 %

N/A

USD7.50M

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -34.29% 68% D+ 38% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -34.29% 68% D+ 38% F
Trailing 12 Months  
Capital Gain -12.86% 87% B+ 59% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -12.86% 87% B+ 57% F
Trailing 5 Years  
Capital Gain -8.44% 69% D+ 40% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -8.44% 69% D+ 34% F
Average Annual (5 Year Horizon)  
Capital Gain 0.92% 48% F 45% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 0.92% 48% F 41% F
Risk Return Profile  
Volatility (Standard Deviation) 47.21% 61% D- 31% F
Risk Adjusted Return 1.95% 48% F 37% F
Market Capitalization 2.17B 91% A- 80% B-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 8.54 10% F 9% F
Price / Cash Flow Ratio -10.74 82% B- 78% C+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -110.34% 24% F 11% F
Return on Invested Capital -31.38% 73% C 27% F
Return on Assets -16.59% 75% C 24% F
Debt to Equity Ratio 126.67% 13% F 17% F
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 7.31 33% F 18% F
Short Percent 9.75% 23% F 18% F
Beta 1.42 47% F 29% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.